芪参清肝汤对拉米夫定抗乙型肝炎病毒治疗应答的影响

Clinical Efficacy of Qishen Qinggan Decoction Combined with Lamivadine for Treatment of Chronic Hepatitis B

目的:研究芪参清肝汤对拉米夫定抗乙肝病毒治疗应答的影响。方法:将79例慢性乙型肝炎患者随机分为两组,治疗组41例以芪参清肝汤联合拉米夫定治疗,对照组38例以拉米夫定治疗,疗程52周,观察治疗前后血清乙肝病毒载量、乙肝标志物、肝功能的变化。结果:疗程结束,治疗组与对照组乙肝病毒转阴率(<1 000拷贝/mL)分别为92.68%和76.31%,差异显著(P<0.05)。HBeAg阴转率分别为46.67%和20.69%,差异显著(P<0.05);HBeAg血清学转换率分别为33.33%和17.24%,差异无统计学意义;乙肝病毒变异发生率分别为4.88%和10.52%,差异无统计学意义。两组治疗后肝功能(ALT,AST,TBil,Alb)均较治疗前明显改善(P<0.05,P<0.01)。结论:芪参清肝汤能提高拉米夫定抗乙肝病毒治疗的应答率。

Objective：To study clinical efficacy of Qishen Qinggan Decoction combined with lamivadine for treatment of chronic hepatitis B（CHB）.Method：Seventy-nine CHB patients were randomly divided into two groups,41 were involved in treatment group,38 were involved in control group.The treatment group were treated by Qishen Qinggan Decoction combined with Lamivadine,the control group was treated by lamivadine.Fifty-two weeks for a course of treatment.Serum level of HBV DNA,HBV-M,liver function were detected to compare the therapeutic effect.Result：Baseline characteristics were well balanced between two groups.The serum HBV DNA became undetectable（1 000 copies/mL）in 92.68% of treatment group vs 76.31% of control group（P0.05）.The rates of serum HBeAg became negative between 2 groups,were 46.67% vs 20.69%（P0.05）.The rates of serum HBeAg seroconversion between 2 groups were 33.33% vs 17.24%.The rates of hepatitis B virus variation between 2 groups were 4.88% vs 10.52 %.Liver function（ALT,AST,TBil,ALb）was significantly improved in both groups（P0.05,P0.01）.Conclusion：Qishen Qinggan Decoction combined with Lamivadine for the treatment of CHB has better virus responsion.